Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm.“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much ...